Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orencia in ANCA-associated Vasculitis
NCT00482066Phase 2Terminated
- Sponsor
- Imperial College London
- Start
- Nov 2007
- Primary completion
- Nov 2008
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of abatacept in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Imperial College London. Started Nov 2007; status: terminated.
02
Drugs
abatacept
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT00482066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00482066.